|
|
|
| Comparison of the Application of Protein Succinylate Iron Oral Solution Combined with Rosuvastatin or rhEPO in Non-Dialysis Renal Anemia Patients |
| SONG Dali, YUAN Ling, WANG Xiaojuan, et al |
| The First Affiliated Hospital of Anhui University of Technology / Huainan First People's Hospital, Anhui Huainan 232007, China |
|
|
|
|
Abstract Objective: To compare the application effects of protein succinylate iron oral solution combined with rosuvastatin or combined with recombinant human erythropoietin (rhEPO) in non-dialysis renal anemia patients. Methods: A total of 120 inpatient and outpatient non-dialysis renal anemia patients admitted to our hospital from April 2020 to October 2022 were selected and divided into two groups using a simple randomization method. The control group was treated with protein succinylate iron oral solution combined with rhEPO, while the observation group was treated with protein succinylate iron oral solution combined with rosuvastatin. Differences in renal function indicators, anemia indicators, and iron metabolism indicators between the two groups were examined, and the incidence of adverse reactions was recorded. Results: There was no significant difference in renal function related factors between the two groups before and after treatment (P>0.05). There was no significant difference in renal function index between observation group and control group before and after treatment (P>0.05).There was no significant difference in anemia-related indicators between the two groups before treatment (P>0.05). Compared with before treatment, hemoglobin (Hb) and erythrocyte specific volume (HCT) of the two groups were increased after treatment, and the difference of Hb and HCT before and after treatment of the observation group was greater than that of the control group (P<0.05), and the immature reticulum ratio (IRF) between the two groups before and after treatment had no significant difference (P>0.05). There was no significant difference in iron metabolism between the two groups before treatment (P>0.05). Compared with the control group before treatment, the saturation of ferritin and transferrin in the two groups increased after treatment, and the total iron binding capacity decreased after treatment. The difference of iron metabolism indexes in the observation group before and after treatment was greater than that in the control group (P<0.05). The cumulative incidence of adverse reactions in the observation group was 11.67% (7/60) compared with 10.00% (6/60) in the control group, with no significant difference (P>0.05). Conclusion: The treatment of non-dialysis renal anemia with protein succinylate iron oral solution combined with rosuvastatin shows better improvement in anemia and iron metabolism indicators than the combination with rhEPO. At the same time, it ensures safety and is worthy of clinical recommendation.
|
|
|
|
|
|
[1] 任翔,过轶斌,张立元.罗沙司他对重组人促红细胞生成素疗效不佳血液透析肾性贫血患者血生化、铁代谢和钙磷代谢的影响[J].陕西医学杂志,2023,52(7):902-905,915.
[2] 张洁,张莹莹,丘江.加味四物汤联合促红细胞生成素对肾性贫血红细胞参数、肾功能及微炎症状态的影响[J].湖北中医药大学学报,2021,23(2):59-62.
[3] 肾性贫血诊断和治疗共识中国专家组.肾性贫血诊断与治疗中国专家共识[J].中华肾脏病杂志,2013,29(5):389-392.
[4] 袁新科,周璐婷,田俊玮,等.罗沙司他对非透析糖尿病肾脏疾病患者肾性贫血的疗效和安全性分析[J].中国实用内科杂志,2023,43(1):69-73.
[5] 成水芹,周婷婷,张志宏,等.罗沙司他和重组人促红细胞生成素对腹膜透析患者血压及心脑血管并发症的影响[J].肾脏病与透析肾移植杂志,2022,31(1):9-14.
[6] 黄思梅,胡煜琳.罗沙司他与重组人促红素联合静脉铁剂治疗铁达标的维持性血液透析患者肾性贫血的疗效比较[J].中国临床医生杂志,2023,51(5):574-577.
[7] 胡宝丽,胡斌.罗沙司他治疗肾性贫血的研究进展[J].基础医学与临床,2022,42(9):1449-1453.
[8] 谷茜,景三辉,吴歌.罗沙司他口服治疗肾性贫血效果观察[J].山东医药,2022,62(12):60-63.
[9] 李彩凤,胡玉清,梁萌.罗沙司他治疗非透析慢性肾脏病患者肾性贫血疗效观察[J].中国中西医结合肾病杂志,2022,23(8):692-694.
[10] 王荣忠,樊萍,陈慧,等.罗沙司他联合重组人红细胞生成素治疗维持性血液透析肾性贫血临床观察[J].中国药业,2022,31(24):79-82. |
|
|
|
2023, Vol. 29 
